Trial · NCT05008939
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rates of treatment responses in 17-item Hamilton Depression Rating Scale (HDRS-17) | 24 hours after the end of treatment | ≥50% HDRS-17 reduction in depressive symptoms |
| Secondary | Rates of treatment responses in HDRS-17 | 2 hours, 7 days,14 days and 28 days after the end of treatment | ≥50% HDRS-17 reduction in depressive symptoms |
| Secondary | Rates of remissions in HDRS-17 | 2 hours, 24 hours, 7 days,14 days and 28 days after the end of treatment | HDRS-17 ≤7 points |
| Secondary | Rates of treatment responses in Montgomery-Åsberg Depression Rating Scale (MADRS) | 2 hours, 24 hours, 7 days,14 days and 28 days after the end of treatment | ≥50% MADRS reduction in the baseline score |
| Secondary | Rates of remissions in MADRS | 2 hours, 24 hours, 7 days,14 days and 28 days after the end of treatment | MADRS \<10 |
| Secondary | The assessment of depression with self-rating scale | 2 hours, 24 hours, 7 days,14 days and 28 days after the end of treatment | The changes of score in Patient Health Questionnaire-9 (PHQ-9) |
| Secondary | The assessment of anxiety by psychiatrist | 2 hours, 24 hours, 7 days,14 days and 28 days after the end of treatment | The changes of score in Hamilton Anxiety Rating Scale (HAMA) |
| Secondary | The assessment of anxiety with self-rating scale | 2 hours, 24 hours, 7 days,14 days and 28 days after the end of treatment | The changes of score in Generalized Anxiety Disorder Screener (GAD-7) |
| Secondary | The assessment of improvement by psychiatrist | 2 hours, 24 hours, 7 days,14 days and 28 days after the end of treatment | The changes of score in Clinical Global Impression (CGI) |
| Secondary | The assessment of improvement with self-rating scale | 2 hours, 24 hours, 7 days,14 days and 28 days after the end of treatment | The changes of score in Patient Global Impressions of Improvement (PGI-I) |
| Secondary | The assessment of side effects with self-rating scale | 2 hours, 24 hours, 7 days,14 days and 28 days after the end of treatment | Including Patient Rated Inventory of Side Effects (PRISE) |
| Secondary | Side effects of sevoflurane | up to 2 hours after the end of treatment | Including nausea, vomiting, headache, dizzy, hypotension, hypoxemia, carbon dioxide accumulation, et al |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05008939/registered